Enoxaparin sodium

• Description:

  Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI) .

• Stability:

  ≥ 2 years

• Purity:

  >98% (HPLC)

• Weight:

  1322

• Molecular Formula:

  C42H59N3Na4O35S2

• Notes:

  Research use only, not for human use.

• Receptor:

  Parasite|N-myristoyltransferase-1 (NMT-1)

• CAS Number:

  679809-58-6